Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...